Last reviewed · How we verify

Pemetrexed Disodium Heptahydrate — Competitive Intelligence Brief

Pemetrexed Disodium Heptahydrate (Pemetrexed Disodium Heptahydrate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; multitargeted antifolate. Area: Oncology.

phase 3 Antimetabolite; multitargeted antifolate Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pemetrexed Disodium Heptahydrate (Pemetrexed Disodium Heptahydrate) — ECOG-ACRIN Cancer Research Group. Pemetrexed is a multitargeted antifolate that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pemetrexed Disodium Heptahydrate TARGET Pemetrexed Disodium Heptahydrate ECOG-ACRIN Cancer Research Group phase 3 Antimetabolite; multitargeted antifolate Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed + oral folinic acid rescue Pemetrexed + oral folinic acid rescue Radboud University Medical Center marketed Antifolate antimetabolite Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Intrathecal injection of pemetrexed Intrathecal injection of pemetrexed Union Hospital, Tongji Medical College, Huazhong University of Science and Technology marketed Antifolate antimetabolite Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed plus Pembrolizumab Pemetrexed plus Pembrolizumab Hunan Province Tumor Hospital phase 3 Antifolate antimetabolite + PD-1 inhibitor combination Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); PD-1 (pembrolizumab)
Pemetrexed + carboplatin Pemetrexed + carboplatin AstraZeneca phase 3 Antifolate antimetabolite + platinum-based chemotherapy combination Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (carboplatin)
Pemetrexed Disodium for Injection Pemetrexed Disodium for Injection Allist Pharmaceuticals, Inc. phase 3 Antifolate antimetabolite Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed therapy Pemetrexed therapy The First Affiliated Hospital with Nanjing Medical University phase 3 Antifolate antimetabolite Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; multitargeted antifolate class)

  1. ECOG-ACRIN Cancer Research Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pemetrexed Disodium Heptahydrate — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-disodium-heptahydrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: